Study on Imaging and Clinical Features of MRONJ by Comparing with Suppurative Osteomyelitis of the Jaw

doi:10.13701/j.cnki.kqyxyj.2024.12.006

Abstract

Abstract: Objective: To summerize the imaging and clinical features of MRONJ (medication-related osteonecrosis of the jaw) by comparing with suppurative osteomyelitis of the jaw. Methods: The imaging and clinical data of patients with MRONJ were retrospectively analyzed with those of patients with suppurative osteomyelitis of the jaw. Results: In the cases of MRONJ, 100% (compared to 14.0% of suppurative osteomyelitis of the jaw) were observed with osteosclerosis, 30.8% (compared to 5.0%) were observed with multiquadrant osteosclerosis, 43.6% (compared to 4.0%) were observed with sequestrum, 25.6% (compared to 0%) were observed with sequestrum and multiquadrant osteosclerosis, and 89.7% (compared to 20.0%) of the inducements were tooth extraction. Conclusion: Compared to suppurative osteomyelitis of the jaw, the probability of oberving osteosclerosis, multiquadrant osteosclerosis, and sequestrum on MRONJ are higher, and when multiquadrant osteosclerosis and sequestrum appear simultaneously, it is very likely to be MRONJ. Tooth extraction is the most major inducement of MRONJ.

Key words: medication-related osteonecrosis of the jaw, biphosphonate, imagigng feature, sequestrum, osteosclerosis

SU Chuanchao, LIN Zitong, WANG Jingfei, GU Zhen, XUE Yiwen, DENG Runzhi. Study on Imaging and Clinical Features of MRONJ by Comparing with Suppurative Osteomyelitis of the Jaw[J]. Journal of Oral Science Research, 2024, 40(12): 1065-1070.

References

[1] AlRowis R, Aldawood A, AlOtaibi M, et al. Medication-related osteonecrosis of the jaw(MRONJ): A review of pathophysiology, risk factors, preventive measures and treatment strategies[J]. Saudi Dent J, 2022, 34(3):202-210.
[2] Aguirre JI, Castillo EJ, Kimmel DB. Preclinical models of medication-related osteonecrosis of the jaw(MRONJ)[J]. Bone, 2021, 153(9):116-184.
[3] Kawahara M, Kuroshima S, Sawase T. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review[J]. Int J Implant Dent, 2021, 7(1):47-58.
[4] Shin JW, Kim JE, Huh KH, et al. Radiological manifestations and clinical findings of patients with oncologic and osteoporotic medication-related osteonecrosis of the jaw[J]. Sci Rep, 2024,14(1):8744-8753.
[5] Reinert CP, Pfannenberg C, Gückel B, et al. Preoperative assessment of medication-related osteonecrosis of the jaw using ¹⁸F fluoride positron emission tomography(PET)/CT and[¹⁸F] fluorodeoxyglucose PET/MRI in correlation with histomorphometry and micro-CT-A prospective comparative study[J]. Diagnostics(Basel), 2024, 14(4):428-443.
[6] Huber FA, Schumann P, von Spiczak J, et al. Medication-related osteonecrosis of the jaw-comparison of bone imaging using ultrashort echo-time magnetic resonance imaging and cone-beam computed tomography[J]. Invest Radiol, 2020, 55(3):160-167.
[7] Obermeier KT, Dewenter I, Malenova Y, et al. Sclerotic bone: a sign of bone reaction in patients with medication related osteonecrosis of the jaw[J]. Sci Rep, 2024, 14(1):7914-7922.
[8] Zara S, De Colli M, di Giacomo V, et al. Zoledronic acid at subtoxic dose extends osteoblastic stage span of primary human osteoblasts[J]. Clin Oral Investig, 2015, 19(3):601-611.
[9] Ruggiero SL, Dodson TB, Aghaloo T, et al. American association of oral and maxillofacial surgeons' position paper on medication-related osteonecrosis of the jaws-2022 update[J]. J Oral Maxillofac Surg, 2022, 80(5):920-943.
[10] Shin JW, Kim JE, Huh KH, et al. Radiological manifestations and clinical findings of patients with oncologic and osteoporotic medication-related osteonecrosis of the jaw[J]. Sci Rep, 2024, 14(1):8744-8753.
[11] Whitefield S, Ilan MB, Lazarovici TS, et al. Medication-related osteonecrosis of the jaw: A cross-sectional study on the prevalence of cutaneous manifestations and the primary care physician's role in its early diagnosis[J]. Am J Med, 2024, 137(3):266-272.
[12] Brauner E, Mezi S, Ciolfi A, et al. A new medical record proposal to the prognostic risk assessment for MRONJ in oncologic patients: "Sapienza head and neck unit" proposal[J]. Int J Environ Res Public Health, 2021, 18(4):1851.
[13] Tani M, Hatano K, Yoshimura A, et al. Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management[J]. Sci Rep, 2024, 14(1):13451-13461.
[14] Campisi G, Fedele S, Fusco V, et al. Epidemiology,clinical manifestations,risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents[J]. Future Oncol, 2014, 10(2):257-275.
[15] Al-Sarraj M, Burns M, Patel V. Pre-existing medication-related osteonecrosis of the jaw before dental extraction[J]. Br Dent J, 2023, 235(10):783-788.
[16] Jiang A, Zhang Z, Qiu X, et al. Medication-related osteonecrosis of the jaw(MRONJ): a review of pathogenesis hypothesis and therapy strategies[J]. Arch Toxicol, 2024, 98(3):689-708.
[17] Pippi R, Giuliani U, Tenore G, et al. What is the risk of developing medication-related osteonecrosis in patients with extraction sockets left to heal by secondary intention? A retrospective case series study[J]. J Oral Maxillofac Surg, 2021, 79(10):2071-2077.
[18] Dunphy L, Salzano G, Gerber B, et al. Medication-related osteonecrosis(MRONJ) of the mandible and maxilla[J]. Drug Ther Bull, 2020, 58(11):172-175.